ATTR program on hold amid safety risks; HAE therapy faces tough rivals and small market. Read more analysis here.
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect pharmacies to support ...
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback